June 24th 2025
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
February 17th 2025
NIIMBL Receives Federal Funding for Biopharmaceutical Manufacturing Projects
July 16th 2021The US federal government awarded new funding to the National Institute for Innovation in Manufacturing Biopharmaceuticals, including funding under the American Rescue Plan that will be used to advance vaccine manufacturing.
EMA Issues Positive Opinion for CrisBio Developed Vaccine, Validating the Platform
June 22nd 2021EMA's recent positive opinion for a recombinant vaccine for rabbits developed using Algenex’s proprietary and patent protected Baculovirus vector-mediated expression platform, CrisBio, should push the full commercialization of the platform forward.